Revenue Performance - Total revenue for Q3 2022 increased by 6.5% to HKD 4,374 million, with HKD 3,599 million from the tissue segment and HKD 775 million from personal care[2] - For the nine months ended September 30, 2022, total revenue grew by 6.6% to HKD 14,055 million, with HKD 11,562 million from the tissue segment and HKD 2,492 million from personal care[3] - Total revenue for Q3 2022 increased by 6.5% to HKD 4,374 million, with HKD 3,599 million from the tissue segment and HKD 775 million from personal care[6] - Total revenue for the nine months ended September 30, 2022, increased by 6.6% to HKD 14,055 million, with HKD 11,562 million from the tissue segment and HKD 2,492 million from personal care[7] Profitability Metrics - Gross profit decreased by 17.1% to HKD 1,191 million, with a gross margin contraction of 7.8 percentage points to 27.2%[2] - Gross profit for the nine months decreased by 11.2% to HKD 4,291 million, with a gross margin decline of 6.1 percentage points to 30.5%[3] - Operating profit fell by 78.2% to HKD 77 million, resulting in an operating margin decrease of 6.8 percentage points to 1.8%[2] - Operating profit for the nine months decreased by 46.7% to HKD 834 million, with an operating margin contraction of 6.0 percentage points to 5.9%[7] - EBITDA for the nine months decreased by 27.1% to HKD 1,817 million, with an EBITDA margin reduction of 6.0 percentage points to 12.9%[3] - EBITDA decreased by 40.1% to HKD 399 million, with the corresponding EBITDA margin dropping by 7.1 percentage points to 9.1%[6] Exchange Losses - Total exchange loss amounted to HKD 76.5 million for the nine months, compared to a loss of HKD 0.9 million in the same period last year[3] - Total exchange loss amounted to HKD 54.1 million, compared to a loss of HKD 7.5 million in Q3 2021, with HKD 51.1 million from operating activities[6] - Total exchange loss for the nine months was HKD 76.5 million, compared to a loss of HKD 0.9 million in the same period of 2021[7] Strategic Focus - The company plans to focus on brand building and innovation investment to enhance long-term competitiveness[2] - Future strategies include price adjustments, high-end strategies, and cost control to alleviate cost pressures and gradually improve profit margins[2] - The company has experienced unprecedented production cost increases and operational disruptions due to pandemic controls and exchange rate fluctuations[2]
维达国际(03331) - 2022 Q3 - 季度财报